Pharmaceuticals known as biologics are made from living things or parts of them. These medications can come from a variety of biological sources, including human cells, avian cells, yeast cells, bacterial cells, and insect cells, among others. Therapeutic proteins, monoclonal antibodies, and vaccines are components of medications. These medications can be used to treat a variety of chronic conditions, such as cancers, infectious diseases, metabolic diseases, inflammatory diseases, and cardiovascular diseases.
According to Data Bridge Market Research, the Biologics Market is growing with a CAGR of 11.5% in the forecast period of 2023 to 2030 and is expected to reach USD 1,41,276.35 million by 2030.
" Change in lifestyle has driven the market”
The market for biologics has been driven by changes in lifestyle, such as sedentary behavior, unhealthy eating habits, and an aging population. The prevalence of chronic diseases has increased, necessitating more effective and targeted treatments. Personalized medicine and patient preference for biologics have also played a role. Technological advancements and regulatory support have further fueled the market's growth, allowing for the development and accessibility of innovative biologic therapies. Overall, lifestyle changes have created a demand for biologics as a means to address the evolving healthcare needs of the population.
What restraints the growth of the Asia-Pacific Biologics Market?
" Complex manufacturing limit the market growth rate"
The highly complex molecules that make up biologic drugs are created by living cells over the course of a multi-step manufacturing process. These molecules' essential properties, or critical quality attributes, can change depending on post-translational alterations that take place in the cellular setting or during the production process. Numerous defaults are caused by the manufacturing process' complexity. So, a significant barrier to market expansion is the complicated manufacturing process for biologics.
Segmentation: Asia-Pacific Biologics Market
The biologics market is segmented on the basis of class, type, route of administration, application, source material, end user, and distribution channel.
- On the basis of class, the biologics market is segmented into tumor necrosis factor-α (TNF) inhibitors, b-cell inhibitors, interleukin inhibitors, selective co-stimulation modulators (abatacept), and others.
- On the basis of type, the biologics market is segmented into monoclonal antibodies (MABS), therapeutic proteins, vaccines, cellular based biologics, gene based biologics, and others
- On the basis of route of administration, the biologics market is segmented into injection and infusion
- On the basis of application, the biologics market is segmented into oncology, autoimmune diseases, diabetes, infectious diseases, cardiovascular diseases, ophthalmic conditions, dermatological diseases, and others.
- On the basis of source material, the biologics market is segmented into humans, avian cell culture, yeast, bacteria, insects cell culture, transgenics, and others.
- On the basis of end user, the biologics market is segmented into hospitals, specialty clinics, academics and research institutes, and others.
- On the basis of distribution channel, the biologics market is segmented into direct tender, retail sales, and third party distribution.
To know more about the study, visit, Asia-Pacific Biologics Market Growth Factor & Industry Scope | 2030 (databridgemarketresearch.com)
Recent Developments in Asia-Pacific Biologics Market
- In 2021, In partnership with Viatris Inc., Biocon introduced Interchangeable SEMGLEE (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection. The introduction of the new product assisted patients in managing high blood sugar in both adults and children with diabetes types 1 and 2.
- In 2019, The world's lowest dose volume rotavirus vaccine, ROTAVAC 5D, was made available by Bharat Biotech. The Department of Biotechnology, Government of India, and the product launch team collaborated on the creation of the launch.
The Prominent Key Players Operating in the Asia-Pacific Biologics Market Include:
- AbbVie (U.S.)
- AGC Biologics (Germany)
- BeiGene (China)
- Bharat Biotech (India)
- BioDiem (Australia)
- Biogen (U.S.)
- Biocon (India)
- Bristol-Myers Squibb Company (U,.S.)
- Catalent, Inc. (U.S.)
- Celltrion Healthcare Co., Ltd. (South Korea)
- CHIME BIOLOGICS (China)
- Cipla Inc. (India)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. (Japan)
- GlaxoSmithKline plc. (U.K.)
- Innovent (China)
- Intas Pharmaceutical Ltd. (India)
- Ipsen Pharma (France)
- Johnson & Johnson Services, Inc. (U.S.)
- KM Biologics (South Korea)
- MERCK & CO., INC. (U.S.)
- NBHL ltd. (India)
- Panacea Biotec (India)
- Pfizer Inc. (U.S.)
- Qilu Pharmaceutical Co., Ltd. (China)
- Serum Institute of India Pvt. Ltd. (India)
- Shanghai Henlius Biotech, Inc. (China)
- Teva Pharmaceutical Industries Ltd. (Israel)
- WuXi Biologics (China)
- YL Biologics (China)
Above are the key players covered in the report, to know about more and exhaustive list of Asia-Pacific Biologics Market companies contact, https://www.databridgemarketresearch.com/de/contact
Research Methodology: Asia-Pacific Biologics Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, global vs regional and vendor share analysis. Please request analyst call in case of further inquiry.
